180 Life Sciences Corp is a therapeutics biotech company based in Palo Alto, CA, dedicated to revolutionizing the treatment of inflammatory and fibrotic diseases. With a focus on developing drugs that target inflammation at its source, their pipeline consists of three families of drugs aimed at treating various inflammatory conditions, including Dupuytren's Contracture, fibrosis, early arthritis, and more.
Led by world-class scientists with a track record of developing groundbreaking drugs, their lead program for early-stage Dupuytren's Contracture has shown promising results in clinical trials, meeting primary and secondary endpoints with no serious adverse events. With a mission to bring health and vitality to patients suffering from inflammatory diseases, 180 Life Sciences Corp is poised to make a significant impact in the field of medical therapeutics.
Generated from the website
